$3.12
1.42% yesterday
Nasdaq, Jun 13, 10:00 pm CET
ISIN
US53630X1046
Symbol
LPCN
Sector
Industry

Lipocine, Inc. Stock price

$3.12
+0.25 8.54% 1M
-1.90 37.94% 6M
-1.76 36.16% YTD
-5.06 61.92% 1Y
-12.18 79.64% 5Y
-120.64 97.48% 10Y
-846.88 99.63% 20Y
Nasdaq, Closing price Fri, Jun 13 2025
-0.04 1.42%
ISIN
US53630X1046
Symbol
LPCN
Sector
Industry

Key metrics

Market capitalization $16.91m
Enterprise Value $-2.81m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.50
EV/Sales (TTM) EV/Sales -0.77
P/S ratio (TTM) P/S ratio 4.61
P/B ratio (TTM) P/B ratio 0.88
Revenue growth (TTM) Revenue growth -22.08%
Revenue (TTM) Revenue $3.67m
EBIT (operating result TTM) EBIT $-6.47m
Free Cash Flow (TTM) Free Cash Flow $-5.60m
Cash position $19.72m
EPS (TTM) EPS $-1.00
P/E forward negative
P/S forward 21.16
EV/Sales forward negative
Short interest 1.85%
Show more

Is Lipocine, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,847 stocks worldwide.

Lipocine, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a Lipocine, Inc. forecast:

2x Buy
100%

Analyst Opinions

2 Analysts have issued a Lipocine, Inc. forecast:

Buy
100%

Financial data from Lipocine, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
3.67 3.67
22% 22%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 4.55 4.55
12% 12%
124%
- Research and Development Expense 5.59 5.59
43% 43%
152%
-6.42 -6.42
38% 38%
-175%
- Depreciation and Amortization 0.05 0.05
25% 25%
1%
EBIT (Operating Income) EBIT -6.47 -6.47
38% 38%
-176%
Net Profit -5.37 -5.37
40% 40%
-146%

In millions USD.

Don't miss a Thing! We will send you all news about Lipocine, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Lipocine, Inc. Stock News

Neutral
PRNewsWire
5 days ago
New Drug Submission filed by Lipocine's licensing partner Verity Pharma Over 700,000 total prescriptions written annually for testosterone replacement therapy (TRT) in Canada, representing large commercial opportunity SALT LAKE CITY , June 9, 2025 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to enable effective oral del...
Neutral
PRNewsWire
23 days ago
SALT LAKE CITY , May 22, 2025 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced that its development candidate LPCN 1148 for men with cirrhosis is featured in the "Hepatology Highlights" section of the June 2025 edition of Hepatology. The article "LPCN ...
Neutral
PRNewsWire
about one month ago
SALT LAKE CITY , May 14, 2025 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced that it will present at A.G.P.'s Annual Healthcare Company Showcase being held virtually on Wednesday, May 21, 2025.
More Lipocine, Inc. News

Company Profile

Lipocine, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development for the delivery of drugs using proprietary delivery technology. The firm involves in applying oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. It offers TLANDO, an oral testosterone replacement therapy. The company was founded in 2011 and is headquartered in Salt Lake City, UT.

Head office United States
CEO Mahesh Patel
Employees 16
Founded 2011
Website www.lipocine.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today